TITLE 30: PROFESSIONS AND OCCUPATIONS

PART 3001: MISSISSIPPI PHARMACY PRACTICE REGULATIONS

ARTICLE XLIII PRESCRIPTION MONITORING PROGRAM

The Mississippi Board of Pharmacy shall operate a Prescription Monitoring Program (PMP) as provided for in Mississippi Code Annotated Section 73-21-127.

1. In addition to the provisions of Mississippi Code Annotated Section 73-21-127, the following reporting provisions shall apply:
   a. Direct administration of a controlled substance to the body of an ultimate user (such as in an inpatient setting) is exempt from reporting.
   b. Any quantity of drug dispensed that is limited to an amount adequate to treat the ultimate user for 48 hours or less is exempt from reporting.
   c. Dispensing by a veterinarian is exempt, however prescriptions written by a veterinarian and filled by a pharmacy are required to be reported by the pharmacy.
   d. Controlled substance prescriptions dispensed for patients in nursing homes, ICFMRs, and Assisted Living facilities ARE required to be reported.
   e. Mail Order pharmacies (in Mississippi, or shipping into Mississippi) shall report to the Mississippi Prescription Monitoring Program.
   f. Pharmacies shall report controlled substance dispensing information every twenty-four (24) hours or the next business day.

2. The Board may specify a uniform electronic format for the mandatory reporting, sharing, and disclosure of PMP information. Dispensers will submit information as required by the Prescription Monitoring Program. Any reporting errors shall be corrected by the dispensers within seven (7) working days of being notified of the error. The Board may develop guidelines for the registration and use of the Prescription Monitoring Program. Failure to follow the Board approved guidelines may result in disciplinary action.

3. It is the intent of the Board that pharmacists utilize the PMP on a regular basis based on their professional judgment.

4. Prior to dispensing a prescription for a Schedule II opiate, a pharmacist shall review the prescription monitoring program based on any of the following circumstances:
   a. The patient is a new customer to that pharmacy; or
   b. The patient has not had an opioid prescription filled at that pharmacy within six (6) months;

5. The prescription monitoring program shall be reviewed at least once every six (6) months for any patient receiving controlled substances.